Skip to Main Content

American taxpayers may have provided $162 million toward researching remdesivir, but the federal government does not have patent rights for the drug because the work contributed by U.S. scientists did not generate any inventive new uses, according to a government report.

Moreover, Gilead Sciences, which discovered remdesivir, had already reached collaborative research deals with various federal agencies and universities to work on its existing portfolio of patents and patent applications, including for the remdesivir compound. And this “would have left little room for the agencies to generate their own patents, the Government Accountability Office found.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • Back in the day, between 1992 and 2000, physicians researched Azacytidine for myelodysplasia when it was a free, expanded access drug manufactured by Ben Venue pharmaceuticals. Then a medium sized registration study was done, it was approved and it was suddenly 4,000 dollars a month. The 8 years of hematologists using the drug and reporting results meant nothing. It happens

    • Hi Bob,

      Thanks for stopping by. And yes, the link is there. I’ve been updating every few minutes.

      Hope all is well,
      ed at pharmalot

Comments are closed.